Radius Pharmaceuticals – Phase 3, Randomized trial of Elacestrant vs. Standard of Care in patients with Metastatic breast cancer who have progression of disease following a CDK 4/6 Inhibitor
Roche – Phase 3 double-blind placebo controlled randomized study of Ipatasertib in combination with Atezolizumab and Paclitaxel for metastatic Triple Negative Breast Cancer
Helsinn Healthcare – Phase 3, randomized, double blind study to evaluate the effectiveness and safety of Anamorelin for treatment of malignancy associated with Anorexia and weight loss in NSCLC
Array/Optimal Network – 1st/2nd Line study of Encoratenib + Benimetnib in patients With BRAF V600 positive non-small cell lung cancer;
BMS 2099KD – Phase 2 study of Nivolumab with Rucaparib(Arm A), Docetaxel (Arm B), or Enzalutamide (Arm C) in Metastatic prostate cancer; must have HRD positive disease
Clinical trials are studies that evaluate the effectiveness of new drugs or treatment strategies. The development of more effective cancer treatments requires that new and innovative therapies be evaluated with cancer patients. In oncology, clinical trials are especially important because, in the absence of high cure rates, nearly all therapeutic approaches are developmental in nature. All new cancer drugs that are currently available in the United States were once only available in clinical trials. Patients should decide whether or not participation in a clinical trial is an appropriate treatment option as early in their evaluation as possible because, once treatment of their cancer has been initiated, patients may become ineligible to participate in some clinical trials.